Nutra Pharma has selected Nutritional Alliance to serve as its global sales agent for its Nyloxin pain relievers intended for the human and animal health markets; Nutritional Alliance is considered one of the premier sales brokerage firms in the United States, specializing in products distributed through food, drug and mass retailers as well as medical product distributors.
Nutra Pharma Corporation, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has selected Nutritional Alliance to serve as its global sales agent for its Nyloxin pain relievers.
“We are pleased to introduce Nutritional Alliance as our global sales agent. This relationship provides Nutra Pharma with access to an important multinational network of leading medical product distributors and international retailers. Additionally, this is a natural continuation of our product launches that began with the introduction of Cobroxin last November,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Over the past several months, we have worked diligently with Nutritional Alliance to prepare for our domestic launch of Nyloxin through one of the largest healthcare product distributors, Henry Schein. We look forward to continuing to work closely with the team at Nutritional Alliance as we expand our Nyloxin distribution worldwide,” he concluded.
Founded in 2000, Nutritional Alliance has grown into one of the premier sales brokerage firms in the United States specializing in products intended for food, drug and mass distribution as well as products intended for medical distribution. Currently, Nutritional Alliance works with many of the largest retailers and medical product distributors throughout North America, Europe and South America.
“We are honored to be partnering with Nutra Pharma on the distribution and growth of Nyloxin,” commented Jim Airaghi, Founder and President of Nutritional Alliance. “Based on the feedback we have already received from potential domestic and international distributors, we believe that Nyloxin will be one of the most exciting healthcare products of 2011,” he added.
In addition to working with Nutra Pharma on the distribution of Nyloxin for the human health market, Nutritional Alliance will also be partnering with the Company on the launch and distribution of Nyloxin for Pets, a product introduced in September for the treatment of moderate to severe chronic pain in companion animals.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Nutritional Alliance becoming the Company’s global sales and distribution agent should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.